Loading
CC
Chemed Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Aug 2025.
Chemed Corp: what insiders have been doing
Every trade that managers of Chemed Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 34 filings came from 13 insiders.
The flow runs one way only: 11 sales worth €6.3M, from 5 insiders, and no purchase. The totals exclude 1 filing filed without an amount. One trade stands out by size: a sale of €936k from Mcnamara Kevin J, disclosed on 4 August 2026, or 0.016% of market capitalisation.
Compared with its exchange (5,813 companies, median 19 filings), a count of 34 filings is above the norm. Our records for Chemed Corp go back to 2016, with 2 purchases and 78 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 2.53 bn USD and net income at 265.2 m USD; the dividend was 2.20 USD per share.
Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
207
Thresholds
n/a
Buy Volume
€144,239
2 ops. · all time
Sell Volume
€74M
78 ops. · all time
Who traded when
BuySaleKevin J. Mcnamara12 sales
Spencer S. Lee6 sales
George J. Walsh III1 buy1 sale
Patrick P. Grace2 sales
Andrea R. Lindell1 sale
Brian C. Judkins1 buy
+1 other insider
Since the insiders bought
- +28.1%Entry US$428.91 · Close at T+365 US$549.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,746 of 24,148 companies
62.6
score / 100
Value52
Quality74
FCF yld4.9%
Earn yld4.0%
EV/EBITDA16.2x
ROE27%
Gross mgn33%
Net mgn10%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$512.38
Analyst consensus
5 analysts2.20/5
US$520.00Target US$571.60(+12%)US$650.00
Income statement
RevenueUS$2.5B
Gross profitUS$823.2M33% margin
EBITDAUS$422.4M17% margin
Net incomeUS$265.2M10.6% margin
Valuation
PER (trailing)25.2x
PER (forward)18.6x
P/Book8.0x
Beta0.51
Balance sheet & cash
Market capUS$6.7B
Total debtUS$143.8M
Free Cash FlowUS$325.5M
Debt / Equity35%
Profitability & ownership
ROE27.1%
ROA13.5%
% insiders1.9%
% institutions106.2%
Last declaration on 1 October 2026
Declarations207 total
12,099 shares@ US$445.350.080% mcap19.7% of flowCapital StockSEC:0001193125-26-410313:0
11,160 shares@ US$508.930.084% mcap20.8% of flowCapital StockSEC:0001193125-26-410313:1
2,000 shares@ US$513.450.015% mcap1.1% of flowCapital StockSEC:0001193125-26-408869:0
4,629 shares@ US$445.350.031% mcap15.1% of flowCapital StockSEC:0001193125-26-406299:0
4,270 shares@ US$506.650.032% mcap15.9% of flowCapital StockSEC:0001193125-26-406299:1
2,000 shares@ US$536.130.016% mcap100.0% of flowCommonSEC144:0001628280-26-063702
2,000 shares@ US$499.000.015% mcap1.1% of flowCommonSEC144:0001974078-26-000364
2,000 shares@ US$501.400.015% mcap1.1% of flowCapital StockSEC:0001193125-26-396365:0
2,000 shares@ US$541.160.016% mcap1.1% of flowCapital StockSEC:0001193125-26-362133:0
1,000 shares@ US$541.040.0079% mcap3.2% of flowCapital StockSEC:0001193125-26-362146:0
2,000 shares@ US$539.340.016% mcap50.0% of flowCommonSEC144:0001628280-26-058406
6,786 shares@ US$445.350.044% mcap31.2% of flowCapital StockSEC:0001193125-26-342087:0
5,878 shares@ US$548.960.047% mcap33.3% of flowCapital StockSEC:0001193125-26-342087:1
2,599 shares@ US$445.350.017% mcap46.0% of flowCapital StockSEC:0001193125-26-337649:0
2,270 shares@ US$542.620.018% mcap49.0% of flowCapital StockSEC:0001193125-26-337649:1
19,802 shares@ US$529.220.15% mcap11.1% of flowCapital StockSEC:0001193125-26-331690:1
2,000 shares@ US$539.510.016% mcap1.1% of flowCapital StockSEC:0001193125-26-331690:2
2,001 shares@ US$445.350.013% mcap0.9% of flowCapital StockSEC:0001193125-26-331690:0
2,000 shares@ US$532.250.016% mcap50.0% of flowCommonSEC144:0001628280-26-051760
190 shares@ US$532.000.0015% mcap6.5% of flowCapital StockSEC:0001193125-26-330302:0
223 shares@ US$534.78920.0018% mcap100.0% of flowCapital StockSEC144:0001968582-26-000761
1,347 sharesCapital StockSEC:0001193125-26-265474:0
500 shares@ US$437.830.0032% mcap12.6% of flowCapital StockSEC:0001193125-26-248086:0
1,500 shares@ US$369.370.6% of flowCapital StockSEC:0001193125-26-131183:0
2,000 shares@ US$403.180.8% of flowCapital StockSEC:0001193125-26-105545:0
25 of 207 declarations
About Chemed Corp
Chemed Corp. (NYSE: CHE) is a U.S.-listed company traded on the New York Stock Exchange in the United States, with corporate headquarters in Cincinnati, Ohio. The group is best understood as a two-platform services company built around VITAS Healthcare and Roto-Rooter. Chemed was incorporated in Delaware in 1970 as a subsidiary of W.R. Grace & Co., succeeded to the Special Products Group in 1971, and became independent in 1982. That history matters: Chemed remains a capital-allocation driven holding company with decentralized operating businesses and limited overlap between the two segments.
VITAS is the company’s healthcare platform and one of the largest providers of hospice and end-of-life care in the United States. Its model focuses on non-curative care designed to improve patient comfort and support families through medical, nursing, social, and spiritual services. Roto-Rooter is the second pillar and a leading North American brand in plumbing, drain cleaning, water cleanup, and related emergency restoration services. The two businesses give Chemed a distinct profile: a regulated, reimbursement-sensitive healthcare franchise paired with a more consumer- and property-services-oriented operation that tends to benefit from recurring emergency demand.
Read moreShow less
From a competitive standpoint, VITAS benefits from scale in a market where operational execution, referral networks, staffing, and reimbursement management are critical. Roto-Rooter enjoys strong brand recognition and broad service reach across residential, commercial, and municipal customers. Together, the businesses provide geographic diversification within the U.S. and exposure to different demand drivers, although the company remains primarily domestic. Chemed’s earnings can be influenced by Medicare cap mechanics in hospice, labor costs, and service mix, while Roto-Rooter’s performance is more tied to service volumes, weather patterns, housing-related activity, and pricing.
Recent developments underscore a shareholder-return focus. Chemed reported first-quarter 2026 results on April 23, 2026, and its investor-relations page shows ongoing participation in healthcare conferences during May 2026. Most notably, on May 13, 2026, the board authorized an additional $300 million for share repurchases, reinforcing management’s willingness to return excess capital to shareholders. For investors, Chemed offers an unusual mix of defensive healthcare cash generation and service-led operating leverage, making it a differentiated U.S. NYSE name rather than a pure-play healthcare stock.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
